Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer.

Trial Profile

A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax) in the pre-operative treatment of women with primary breast cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tecemotide (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Letrozole
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ABCSG-34
  • Most Recent Events

    • 03 Dec 2021 Results published in the Clinical Cancer Research
    • 04 Jun 2020 EndoPredict test results published in the Myriad Genetics Media Release.
    • 04 Jun 2020 According to an Myriad Genetics, Inc media release, the company announced the publication of a prospective study demonstrating that the EndoPredict test predicts which patients with ER+, HER2- early-stage breast cancer will benefit from neoadjuvant therapy in the European Journal of Cancer. The test prediction is based on the patients from the ABCSG-34 trial. Peter Dubsky is the lead author, speaking on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top